Ursodeoxycholic acid (UDCA) is a naturally occurring bile acid and is used for dissolving gallstones that are rich in cholesterol. It is also used to improve the flow of bile in primary biliary cirrhosis. UDCA solubilizes cholesterol gallstones, and improves liver function in case of cholestatic diseases. UDCA can be obtained from cholic acid, which is the most abundant and least expensive bile acid available.
Market Dynamics
Factors such as increasing prevalence of gallstones and cystic fibrosis, combined with approval for new indications, is expected to drive market growth over the forecast period. For instance, according to the American Gastroenterological Association 2017 report, gallstones affects 10-15% of the U.S. population annually, which accounts for around 25 million people. In May 2017, IntraBio Ltd. received orphan designation from the European Commission, for ursodeoxycholic acid for the treatment of Niemann-Pick disease. However, the occurrence of possible side effects including nausea, vomiting, itching or dry skin, headache, and sleep disturbances are factors restricting growth of the market.
Key features of the study:
- This report provides in-depth analysis of the ursodeoxycholic acid market and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ursodeoxycholic acid market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as part of this study include Dipharma Francis Srl, ERREGIERRE S.p.A., Grindeks, Industria Chimica Emiliana, Mitsubishi Tanabe Pharma Corporation, Zhongshan Belling Biotechnology Co., Glenmark Pharmaceutical Limited, Abil Chempharma Private Limited, Biotavia Labs Pvt Ltd, Daewoong Bio Inc., PharmaZell GmbH, and Suzhou Tianlu Bio-pharmaceutical Co., Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global ursodeoxycholic acid market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the ursodeoxycholic acid market
Detailed Segmentation:
- Global Ursodeoxycholic Acid Market, By Dosage Form:
- Solid Dosage Form
- Liquid Dosage Form
- Global Ursodeoxycholic Acid Market, By Mode of Extraction:
- Global Ursodeoxycholic Acid Market, By Application:
- Gallstones
- Cystic Fibrosis
- Liver Cirrhosis
- Others
- Global Ursodeoxycholic Acid Market, By Region:
- North America
- By Dosage Form:
- Solid Dosage Form
- Liquid Dosage Form
- By Mode of Extraction:
- By Application:
- Gallstones
- Cystic Fibrosis
- Liver Cirrhosis
- Others
- By Country:
- Latin America
- By Dosage Form:
- Solid Dosage Form
- Liquid Dosage Form
- By Mode of Extraction:
- By Application:
- Gallstones
- Cystic Fibrosis
- Liver Cirrhosis
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Dosage Form:
- Solid Dosage Form
- Liquid Dosage Form
- By Mode of Extraction:
- By Application:
- Gallstones
- Cystic Fibrosis
- Liver Cirrhosis
- Others
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Dosage Form:
- Solid Dosage Form
- Liquid Dosage Form
- By Mode of Extraction:
- By Application:
- Gallstones
- Cystic Fibrosis
- Liver Cirrhosis
- Others
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Dosage Form:
- Solid Dosage Form
- Liquid Dosage Form
- By Mode of Extraction:
- By Application:
- Gallstones
- Cystic Fibrosis
- Liver Cirrhosis
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Dosage Form:
- Solid Dosage Form
- Liquid Dosage Form
- By Mode of Extraction:
- By Application:
- Gallstones
- Cystic Fibrosis
- Liver Cirrhosis
- Others
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Dipharma Francis Srl*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- ERREGIERRE S.p.A.
- Grindeks
- Industria Chimica Emiliana
- Mitsubishi Tanabe Pharma Corporation
- Zhongshan Belling Biotechnology Co.
- Glenmark Pharmaceutical Limited
- Abil Chempharma Private Limited
- Biotavia Labs Pvt Ltd
- Daewoong Bio Inc.
- PharmaZell GmbH
- Suzhou Tianlu Bio-pharmaceutical Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
